Overview

A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection

Status:
Not yet recruiting
Trial end date:
2023-03-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetic profiles of LP-001, an amoxicillin and clavulanate formulation, for use in pediatric patients with a bacterial infection.
Phase:
Phase 1
Details
Lead Sponsor:
Kaizen Bioscience Co.
Treatments:
Amoxicillin
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acid
Clavulanic Acids